Ivan Cohen-Tanugi
Director/Board Member at XBRANE BIOPHARMA AB
Profile
Ivan Cohen-Tanugi is the founder of Minerva Lifesciences GmbH.
He is currently an Independent Director at Xbrane Biopharma AB.
Previously, he served as the Chief Executive Officer of Eyevensys SAS, Kuros Biosciences Ltd., and Senior Vice President-International Operations at Stallergenes SA. He also worked as a Vice President at Amgen International AG.
Dr. Cohen-Tanugi holds an MBA from École des Hautes Études Commerciales de Paris and a doctorate from the University of Grenoble.
Ivan Cohen-Tanugi active positions
| Companies | Position | Start |
|---|---|---|
| XBRANE BIOPHARMA AB | Director/Board Member | 2019-05-15 |
| Minerva Lifesciences GmbH | Founder | - |
Former positions of Ivan Cohen-Tanugi
| Companies | Position | End |
|---|---|---|
| KUROS BIOSCIENCES AG | Chief Executive Officer | 2017-12-03 |
| Amgen International AG | Corporate Officer/Principal | - |
| STALLERGENES | Chief Operating Officer | - |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Chief Executive Officer | - |
Training of Ivan Cohen-Tanugi
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
| University of Grenoble | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| XBRANE BIOPHARMA AB | Health Technology |
| KUROS BIOSCIENCES AG | Health Technology |
| Private companies | 4 |
|---|---|
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
| Amgen International AG | |
| Minerva Lifesciences GmbH |
- Stock Market
- Insiders
- Ivan Cohen-Tanugi
